Why the study?
To identify signature genes mediating the effects of type 2 diabetes on CABG and elucidate their molecular mechanisms and therapeutic value.
Population
Multi-cohort T2D and CABG datasets, clinical CABG patients, and human aortic smooth muscle cells
Design
Bioinformatics analysis, machine learning, clinical validation, and in vitro experimental study
Key result
MINPP1, HES4, and SLCO5A1 were identified as core signature genes mediating the adverse effects of type 2 diabetes on coronary artery bypass grafting, with diagnostic AUC values > 0.625.
Authors
Loading...
Does not yet support gene-based risk tools in diabetic CABG; leaves open prospective validation of these signatures.
MINPP1, HES4, and SLCO5A1 are identified as key signature genes mediating the adverse effects of type 2 diabetes on CABG outcomes, offering potential novel therapeutic targets.
Wang et al. (2026) studied Type 2 diabetes and coronary artery bypass grafting. Type 2 diabetes was evaluated on Identification of core signature genes mediating the adverse effects of T2D on CABG. MINPP1, HES4, and SLCO5A1 were identified as core signature genes mediating the adverse effects of type 2 diabetes on coronary artery bypass grafting, with diagnostic AUC values > 0.625.